Brivaracetam (BRV) improved seizure frequency both as first add-on and late adjunctive treatment in patients with focal epilepsy.

The median daily dose at 12 months was 125 mg and 200 mg in the early and late add-on groups.

Sustained seizure frequency reduction was greater and retention rate was higher for BRV as an early add-on treatment.

Adjunctive BRV was generally well tolerated in clinical practice and most adverse events were mild.

The most common adverse events included somnolence, nervousness and/or agitation, vertigo, and fatigue.